MedTrace Logo

A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma

NCT02743780 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 191

Last updated 2018-07-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if the clinical profile of topical-ocular MGV354 merits further development for the indication of lowering intraocular pressure (IOP).

Conditions

Interventions

DRUG

MGV354 ophthalmic suspension

DRUG

MGV354 placebo

Inactive ingredients used as placebo comparator

Sponsors & Collaborators

  • Novartis Institute for BioMedical Research

    collaborator UNKNOWN

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Clinical Science Expert, NIBR · Novartis Institute for BioMedical Research

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-02
Primary Completion
2016-09-20
Completion
2016-09-20

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02743780 on ClinicalTrials.gov